Chart 2.
Estimated degree of mean weight reduction associated with anti-obesity medications, as well as the percent achievement of weight reduction ≥5, ≥10%, ≥15%, and ≥20%.
| Anti-obesity medication | Mean percent and categorical percent weight reductions∗ | Notes | References |
|---|---|---|---|
| Phentermine 15 mg per day (oral) | Overall mean = 7% ≥5% = 46% ≥10% = 21% ≥15% = NA |
The placebo group had a 2% mean weight reduction, with 16% and 7% achieving ≥5% and ≥10% weight reduction, respectively | [37] [38] |
| Semaglutide 2.4 mg subcutaneously once weekly | Overall mean = 15% ≥5% = 86% ≥10% = 69% ≥15% = 51% ≥20% = 32% |
The placebo group had a 2% mean weight reduction, with 32%, 12%, 5% and 2% achieving ≥5%, ≥10%, ≥15%, and ≥20% categorical weight reduction, respectively | [43] |
| Liraglutide 3.0 mg subcutaneously once daily | Overall mean = 8% ≥5% = 63% ≥10% = 33% ≥15% = 14% |
The placebo group had a 3% mean weight reduction, with 27%, 11%, and 4% achieving ≥5%, ≥10%, and ≥15% categorical weight reduction, respectively | [103] |
| Phentermine HCl/Topiramate Extended Release (oral) (top dose = phentermine 15 mg/92 mg topiramate) |
EQUATE 28-week study: [38] Overall mean = 9% ≥5% = 66% top dose ≥10% = 41% top dose ≥15% = NA SEQUEL 56-week extension study: [104] Overall mean = 10% ≥5% = 79% top dose ≥10% = 54% top dose ≥15% = 32% top dose ≥20% = 15% top dose |
EQUATE 28-week study: [38] The placebo group had a 2% mean weight reduction, with 16% and 7% achieving ≥5% and ≥10% categorical weight reduction respectively SEQUEL 56-week extension study: [104] The placebo group had a 2% mean weight reduction, with 30%, 12%, 7%, and 2% achieving ≥5%, ≥10%, ≥15% and ≥20% categorical weight reduction respectively |
[38] [104] |
| Naltrexone sustained release (SR) 32 mg/day plus bupropion SR 360 mg/day (oral) | Overall mean = 7% ≥5% = 56% ≥10% = 27% ≥15% = 10% |
The placebo group had a 2% mean weight reduction with 18%, 7%, and 2% achieving ≥5%, ≥10%, and ≥15% categorical weight reduction, respectively | [47] |
| Orlistat 120 mg three times per day (oral) | Overall mean = 9% ≥5% = 66% ≥10% = 39% ≥15% = NA |
The placebo group had a 6% weight reduction with 44% and 25% achieving >5% and >10% categorical weight reduction, respectively | [105] |
| Non-systemic Oral Hydrogel, three 2.25-g capsules before lunch and dinner (oral) | Overall mean = 6% ≥5% = 59% ≥10% = 27% ≥15% = NA |
The placebo group had a 4% mean weight reduction with 42% and 15% achieving ≥5% and ≥10% categorical weight reduction, respectively | [106] |
| Tirzepatide (subcutaneous once a week) Approved and indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, but investigational for treatment of obesity at the time of publication ∗∗ | Overall mean = 21% (15 mg) ∗∗ ≥5% = 91% 15mg ≥20% = 57% 15mg |
The placebo group had a 3% mean weight reduction with 35% and 3% achieving ≥5% and ≥20% categorical weight reduction, respectively | ∗∗ |
NA = Not available (data was not found).
∗ The values in this chart are not intended to represent head-to-head comparisons. Data are derived from different studies. In most cases, the percent weight reductions were dose dependent. Therefore, the listed mean values may be less than the percent weight reduction with the highest doses of anti-obesity medications.
∗∗ Preliminary treatment-regimen estimand results from a News Release on April 28, 2022: https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-delivered-225-weight-loss-adults-obesity-or. Tirzepatide Prescribing information: https://pi.lilly.com/us/mounjaro-uspi.pdf?s=pi.